Dec 12,2022

Machine learning in radiology: the new frontier in interstitial lung diseases

Machine-learning algorithms can identify ILD in at-risk populations, predict the extent of lung fibrosis, correlate radiological abnormalities with lung function decline, and be used as endpoints in treatment trials, exemplifying how this technology can be used in care for people with ILD. The purpose of this Review is to describe the clinical and research gaps in the diagnosis and prognosis of ILD, and how machine learning can be applied to image biomarker research to close these gaps.

CLINICAL STUDY

#ai/software

#ml

View Analyst & Ambassador Comments
Go to original news
Dec 14,2022

Adapting to the burdens of care: a telehealth program for cancer survivors with ostomies

A prospective randomized trial comparing usual care (UC) with an Ostomy Self-Management Training (OSMT) program delivered by telehealth was conducted in patients with ostomies due to cancer. The intervention occurred over 5 weeks with survey administration at baseline, program completion, and 6 months after completion. Quantitative data were analyzed using a mixed-effects logistic model to predict mean values of resource and service use. Responses to the open-ended question were coded and analyzed with directed content analysis.

CLINICAL STUDY

#telehealth

View Analyst & Ambassador Comments
Go to original news
Dec 15,2022

Data Published in JCEM Demonstrate Strong Real-World Performance of Veracyte’s Afirma GSC in Thyroid Cancer Diagnosis

Veracyte, Inc. today announced that findings demonstrating the strong real-world performance of the Afirma Genomic Sequencing Classifier (GSC) were published in The Journal of Clinical Endocrinology & Metabolism (JCEM). The data, from a meta-analysis of 13 independent studies, show that the Afirma GSC can accurately rule out thyroid cancer in patients with indeterminate thyroid nodules (ITNs) and that, when the test identifies a nodule as suspicious, the patient’s risk of malignancy is consistent with, and higher than, that reported in the test’s original clinical validation (CV) study.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Dec 15,2022

New Data Presented at the 2022 San Antonio Breast Cancer Symposium Shows Early Detection using L-Dex and Intervention Improves Lymphedema Progression-Free Survival

ImpediMed Limited is pleased to announce a poster showing that breast cancer patients receiving early detection of lymphedema using ImpediMed's L-Dex® technology and intervention had statistically higher rates of lymphedema progression-free survival through three years compared to using tape measure was presented at the 2022 San Antonio Breast Cancer Symposium on December 6-10, 2022 in San Antonio, Texas. The primary aim of the PREVENT Trial was published in January 2022 and demonstrated that patients with early detection using L-Dex and at-home intervention with compression garments resulted in a 7.9% rate of chronic lymphedema compared to a 19.2% rate of chronic lymphedema using tape measure.

CLINICAL STUDY

#ai/software

View Analyst & Ambassador Comments
Go to original news
Dec 21,2022

Implementing a web-based system of screening for symptoms and needs using patient-reported outcomes in people with cancer

The purpose of this study is to evaluate the implementation of a web-based system of screening for symptoms and needs in people with diverse cancers in a general hospital in Australia. Screening for symptoms and needs using a web-based portal identified many unmet needs, but the uptake of this intervention by nurses and patients was lower than expected.

CLINICAL STUDY

#telehealth

View Analyst & Ambassador Comments
Go to original news
Dec 27,2022

A systematic review of m-health apps on managing side effects of breast cancer treatment

After breast cancer treatment, women with breast cancer may experience distress caused by treatment side effects, both in physical and psychological aspects. Technology use is increasing in favor among women. Therefore, it is essential to update the scientific evidence regarding mobile and web apps’ effectiveness in managing the side effects of breast cancer treatments for breast cancer survivors. The purpose of this systematic review was to investigate the scientific evidence on the effectiveness of mobile and web apps in managing the side effects of breast cancer treatments among this group.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Dec 30,2022

Effect and feasibility of gamification interventions for improving physical activity and health-related outcomes in cancer survivors: an early systematic review and meta-analysis

Despite the well-documented advantages of regular physical activity (PA), patients with cancer show suboptimal participation. By using game design elements, gamification could be used to motivate individuals to engage in PA. There are, however, inconsistent findings regarding the impact of gamification interventions on cancer survivors’ PA and health-related outcomes, according to the literature. The aim of this study is to examine the effectiveness and feasibility of gamification interventions for improving physical activity (PA) and health-related outcomes among cancer survivors.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Sep 20,2017

Propeller Health presents data on asthma and COPD at the European Respiratory Society International Congress

Today, Propeller Health released the results from three new asthma and COPD studies presented last week at the European Respiratory Society International Congress (ERS) in Milan, Italy. The five-day event is the world’s largest respiratory health meeting. The company shared interim results on the feasibility and clinical impact of a digital health intervention (Propeller) among a Medicare population with COPD. This study monitored 201 participants over a six-month period, and demonstrated a significant decrease in short-acting bronchodilator (SABA) use and an increase in symptom-free days.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Nov 26,2018

Nationwide asthma study from Propeller Health demonstrates clear link between air pollution and rescue inhaler use

New research from Propeller Health, the University of Wisconsin-Madison and the University of California, Berkeley, is the first nationwide study to show an association between daily air pollution and rescue inhaler use using data obtained objectively from digital medicines. The study, conducted from 2012 to 2017 on more than 2,800 people with asthma and published this week in Proceedings of the National Academy of Sciences, uses one of the largest nationwide datasets to assess the relationship between air pollution and asthma symptoms.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Dec 02,2019

COPD Outcomes Improved Significantly When Patients and Doctors Used a Digital Health Tool, Propeller Health Study Finds

Patients with chronic obstructive pulmonary disease (COPD) at Louisville’s JenCare Senior Medical Center, a ChenMed company, saw their health outcomes improve significantly when their primary care physicians (PCPs) encouraged using Propeller’s digital health tool to manage their COPD, reports new research by Propeller Health, JenCare, ChenMed and the Center for Healthy Air, Water and Soil investigators published in JMIR Formative Research.

CLINICAL STUDY

#mobile app

#virtual care

View Analyst & Ambassador Comments
Go to original news
Subscribe to CLINICAL STUDY